Analysis of the reasons why some patients are not recommended to take Mobosetinib (Anvili)

Mobocertinib is an oral targeted drug targeting EGFR exon 20 insertion mutations and has unique advantages in the treatment of non-small cell lung cancer (NSCLC). However, not all patients are clinically suitable for this drug. First of all, the target of the drug determines that it is suitable for a narrow range of people, mainly targeting patients with EGFR 20 exon insertion mutations confirmed by genetic testing. If the patient does not have this gene mutation, not only will the efficacy of mobosetinib not be achieved, but he may also be exposed to the risk of unnecessary side effects.

Mobosetinib may cause obvious adverse reactions during clinical use, such as diarrhea, rash, electrocardiogramQT interval prolongation, and abnormal cardiac function. For patients with severe heart disease, long-term electrolyte imbalances, or other high-risk underlying conditions, these side effects may aggravate the condition or even cause serious complications. Therefore, doctors usually conduct a comprehensive assessment of the patient's heart function, liver and kidney function, and overall health status before prescribing this drug to avoid potential drug risks.

The pharmacokinetic properties of mobosetinib also make its use unsuitable for some patients. The drug is mainly metabolized by the liver. If the patient has severe liver function damage or takes drugs that affect the CYP3A4 metabolism pathway at the same time, it may lead to an abnormal increase in blood drug concentration and increase the probability of toxic side effects. In addition, the safety data of mobosetinib are currently mainly derived from clinical trials of specific populations. Research data on the elderly, pregnant women, and lactating women are limited, so these groups need to be treated with extreme caution.

Economic and compliance factors may also be reasons for limiting medication use. The price of mobosetinib is relatively high, and it is not included in the scope of medical insurance reimbursement in some areas. For patients with limited economic conditions, the burden of long-term use is heavy. In addition, the drug needs to be taken regularly and health indicators closely monitored during treatment. If patients have difficulty maintaining high compliance, it may affect efficacy and increase risks. Therefore, when deciding whether to use moboxetinib, doctors will comprehensively consider multiple factors such as genetic test results, health status, economic conditions, and patient compliance to ensure drug safety and maximize benefits.

Reference materials:https://www.drugs.com/